A national, multicentric, randomised, controlled trial. Applications of a critical pathway using LEVOFLOXACIN for the management of patients with abnormal PSA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-000805-23-IT

Enrollment

240

Registered

2006-03-13

Start date

2004-09-21

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostatitis MedDRA version: 6.1 Level: SOC Classification code 10038359

Interventions

Trade Name: LEVOXACIN 500 5CPR RIV.500MG Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Levofloxacin CAS Number: 100986-85-4 Concentration unit: mg milligram(s) Concentration type: equal

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Primary end point(s): ;Main Objective: ;Secondary Objective:	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026